Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1 3Phase 4 2Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 10Mesothelioma 3Lung Neoplasms 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thoracic Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Lung Diseases 1Locally Advanced Malignant Neoplasm 1Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

ferric carboxymaltose 2Pemetrexed 2Drug Therapy 2iron isomaltoside 1000 1icotinib 1ferrous sulfate 1elemene 1aumolertinib 1aflutinib 1Rabeprazole 1Gemcitabine 1Docetaxel 1Desflurane 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Adenocarcinoma × Pemetrexed × Clear all
NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
192 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡